Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22902580 | 0.80 | IKBKB (0.53) | IKBKBKMT2AMEN1TSHRKDM4E | |
| SCHEMBL16401445 | 0.78 | KDM4E (0.66) | KMT2AKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL7015986 | 0.77 | MAPT (0.45) | IKBKBKMT2AMEN1TSHRKDM4E | |
| SCHEMBL7008118 | 0.77 | KDM4E (0.53) | KMT2AMEN1TSHRKDM4EALDH1A1 | |
| SCHEMBL7840880 | 0.76 | NUDT1 (0.49) | KMT2AMEN1TSHRKDM4EALDH1A1 | |
| SCHEMBL9271057 | 0.75 | KMT2A (0.51) | IKBKBKMT2AMEN1TSHRKDM4E | |
| SCHEMBL24791172 | 0.73 | NPC1 (0.49) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL14590443 | 0.73 | HSP90AA1 (0.63) | KMT2AMEN1TSHRKDM4EALDH1A1 | |
| SCHEMBL3713427 | 0.73 | KDM4E (0.46) | IKBKBKMT2AMEN1TSHRKDM4E | |
| SCHEMBL3172799 | 0.72 | IKBKB (1.00) | IKBKBKDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534510-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| EP-1267876-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1189618-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1189618-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1187616-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6350745-B1 | DIOXO-(PYRIDOOXAZINE) DERIVATIVES; ANTICOAGULANTS; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020006923-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001070229-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6239132-B1 | PREVENTING CORONARY ARTERY DISEASE, INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION IN A MAMMAL, | MERCK & CO., INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2000074682-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000064449-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006923-A1 | Thrombin inhibitors | F2, F11, F12 | IKBKB 480/4885KMT2A 1794/4885MEN1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.